Figure 2.
Ligand for programmed death-1 (PD-L1) expression in metastatic prostate cancer. (A,B) Immunohistochemistry for PD-L1 in metastatic prostate cancer lesions. The majority of stained lesions are completely PD-L1-negative (A); ∼30% stain positive for PD-L1. (Images courtesy of M. Haffner, Johns Hopkins University.)